Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Amgen to launch US Eylea biosimilar
Regeneron loses bid to block Amgen's Eylea biosimilar launch in US
Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling in its favor on Tuesday, an Amgen spokesperson said. The U.S. Court of Appeals for the Federal Circuit rejected Regeneron's request to block the launch during its appeal of a related decision for Amgen in a patent case in West Virginia.
District Court Denies Regeneron’s Motion For Preliminary Injunction To Block Amgen’s Eylea Biosimilar
On September 23, 2024, Judge Kleeh of the Northern District of West Virginia denied Regeneron Pharmaceuticals, Inc.’s (“Regeneron”) motion for
RBC would buy Regeneron on weakness with biosimilar Eylea priced in
RBC Capital notes that it was announced that the Court of Appeals denied Regeneron’s (REGN) motion for an emergency injunction and the
Amgen to launch US Eylea biosimilar after ruling in Regeneron patent case
Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling in its favor on Tuesday, an Amgen spokesperson said. The U.S. Court of App
34m
AAO 2024: NMA reveals Vabysmo’s superior CST improvement over Eylea HD
This NMA bridges the gap between trials for both therapies and compare them to one another based on existing data.
Managed Healthcare Executive
15h
High-Dose Eylea Shows Unique Properties in nAMD and DME
A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks ...
ENDPOINTS NEWS
15h
Amgen preps to launch Eylea biosimilar years early after Regeneron loses appeal
Amgen is moving forward with the launch of Pavblu, its biosimilar to Regeneron's blockbuster Eylea, following an appeals ...
devdiscourse
6h
Global Health Headlines: Major Developments in Medications and Outbreaks
Recent health news includes a court ruling allowing Amgen's Eylea biosimilar launch, Starboard criticizing Kenvue's skin ...
Managed Healthcare Executive
17h
High-Dose Eylea Offers Longer Treatment Intervals Across Patient Populations with DME
Subgroup analyses of the PHOTON trial show visual acuity gains across subgroups by race, baseline visual acuity and retina ...
3d
Regeneron announces three-year data for EYLEA HD Injection 8 mg study
Regeneron (REGN) announced three-year data for EYLEA HD Injection 8 mg from an extension study of the Phase 3 PHOTON trial in ...
18d
Should You Buy the Dip on This Top Growth Stock?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
11h
Regeneron price target lowered to $1,050 from $1,200 at Wells Fargo
Wells Fargo lowered the firm’s price target on Regeneron (REGN) to $1,050 from $1,200 and keeps an Overweight rating on the shares. Given ...
Managed Healthcare Executive
2d
Positive Results for High-Dose Eylea From Extension Study | AAO 2024
Data about higher doses that are injected less often come as the original 2-milligram dose of Eylea is facing an increasing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Regeneron
Amgen
Aflibercept
Diabetic retinopathy
Feedback